Unravelling the genetic basis of renal diseases; from single gene to multifactorial disorders

Amy J McKnight1, Diane Currie, Alexander P Maxwell

  • 1Nephrology Research Group, Queen's University of Belfast, Belfast BT9 7AB, Northern Ireland, UK.

The Journal of Pathology
|November 3, 2009
PubMed

Insights

Identifying genetic factors for common kidney diseases like diabetic nephropathy is challenging. This review explores strategies and resources for understanding the genetic basis of renal disorders.

Area of Science:

  • Nephrology
  • Genetics
  • Genomics

Background:

  • Chronic kidney disease (CKD) affects up to 5% of adults.
  • Single gene disorders like polycystic kidney disease and Alport syndrome are well-defined genetically.
  • Complex kidney diseases (e.g., diabetic nephropathy) have a less understood genetic basis.

Purpose of the Study:

  • To review current progress in identifying genetic factors for renal disorders.
  • To explore strategies for defining the genetic basis of common and complex kidney diseases.
  • To highlight available renal genetic resources.

Main Methods:

  • Review of linkage studies.
  • Analysis of candidate gene studies.
  • Examination of genome-wide association studies (GWAS).

Main Results:

  • Significant progress has been made in identifying genes for single-gene renal disorders.
  • Identifying genetic susceptibility for complex kidney diseases remains a challenge.
  • Various genetic analysis strategies are being employed.

Conclusions:

  • Understanding the genetic architecture of kidney diseases is crucial for developing targeted therapies.
  • Complementary genetic approaches are essential for comprehensive genetic discovery.
  • Continued research and resource development are needed to unravel the genetic basis of renal disorders.

Related Concept Videos

Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Principles of Pharmacogenetics: Types of Genetic Variants01:27

Principles of Pharmacogenetics: Types of Genetic Variants

The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
Genome-wide Association Studies-GWAS01:11

Genome-wide Association Studies-GWAS

Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
Chronic Kidney Disease I: Introduction01:25

Chronic Kidney Disease I: Introduction

Chronic Kidney Disease (CKD) arises when the kidneys progressively lose their ability to function, ultimately leading to end-stage renal disease. At this advanced stage, the kidneys can no longer filter waste or maintain essential body functions, requiring renal replacement therapy (RRT) through dialysis or a kidney transplant for survival.Early-stage chronic kidney disease and detection challengesIn CKD's early stages, symptoms often remain absent because healthy nephrons compensate for...
Incomplete Dominance01:43

Incomplete Dominance

Gregor Mendel's work (1822 - 1884) was primarily focused on pea plants. Through his initial experiments, he determined that every gene in a diploid cell has two variants called alleles inherited from each parent. He suggested that amongst these two alleles, one allele is dominant in character and the other recessive. The combination of alleles determines the phenotype of a gene in an organism.